Eli Lilly Secures Chinese Approval for Early Symptomatic Alzheimer's Disease Medicine

MT Newswires23:21 ET

Eli Lilly and Co's potential blockbuster new drug donanemab has been approved for sale in China! It is used for treating Alzheimer's disease.

On December 18, Eli Lilly and Co (LLY.US) just announced that its Class 1 new drug donanemab injection application has been approved by the National Medical Products Administration of China (NMPA).

Zhitong Finance20:31 ET

Express News | Lilly's Kisunla™ (Donanemab-Azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

Reuters20:00 ET

Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today

Moomoo Recap US16:03 ET

Peering Into Eli Lilly's Recent Short Interest

Benzinga15:30 ET

Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock

Kevin Travers11:24 ET